Route 92’s Neurovascular Portfolio Approved in Canada

June 22, 2026—Route 92 Medical, Inc. announced that the first commercial cases in Canada were performed with the company’s neurovascular devices. The procedures used the company’s HiPoint 88 system and its Monopoint approach.

The procedures came after receipt of a Health Canada Medical Device License for the company’s portfolio of neurovascular technologies, which includes the HiPoint 70/Tenzing 7 reperfusion system, HiPoint 88/Tenzing 8 reperfusion system, FreeClimb 54/ Tenzing 5 reperfusion system, FreeClimb 70/Tenzing 7 reperfusion system, and Base Camp sheath system.

The first procedures were performed by Vitor Mendes Pereira, MD, at St. Michael’s Hospital in Toronto, Canada. Dr. Pereira is Professor of Surgery and Medical Imaging at the University of Toronto and Director of Endovascular Research and Innovation at St. Michael’s Hospital.

“In the cases we performed, Route 92 Medical’s platform enabled smooth, atraumatic navigation through complex neurovascular anatomy and successful delivery of implants to the target vessels,” commented Dr. Pereira in the company’s press release. “The ability to advance the system without guidewires from a single point of control simplifies access and supports procedural efficiency. Moreover, the telescoping design coupled with the Tenzing delivery catheter allows for atraumatic navigation, particularly in challenging anatomy.”